RU2006111847A - Вакцинные композиции, содержащие интерлейкин 18 и сапониновую адъювантную систему - Google Patents
Вакцинные композиции, содержащие интерлейкин 18 и сапониновую адъювантную систему Download PDFInfo
- Publication number
- RU2006111847A RU2006111847A RU2006111847/13A RU2006111847A RU2006111847A RU 2006111847 A RU2006111847 A RU 2006111847A RU 2006111847/13 A RU2006111847/13 A RU 2006111847/13A RU 2006111847 A RU2006111847 A RU 2006111847A RU 2006111847 A RU2006111847 A RU 2006111847A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- spp
- polypeptide
- virus
- cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 15
- 102000003810 Interleukin-18 Human genes 0.000 title claims 14
- 108090000171 Interleukin-18 Proteins 0.000 title claims 14
- 239000002671 adjuvant Substances 0.000 title claims 12
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims 10
- 229930182490 saponin Natural products 0.000 title claims 10
- 150000007949 saponins Chemical class 0.000 title claims 10
- 229960005486 vaccine Drugs 0.000 title 1
- 230000002163 immunogen Effects 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 230000000975 bioactive effect Effects 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- -1 prostate Proteins 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 208000035473 Communicable disease Diseases 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 102100022144 Achaete-scute homolog 2 Human genes 0.000 claims 3
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims 3
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims 3
- 101000901109 Homo sapiens Achaete-scute homolog 2 Proteins 0.000 claims 3
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 3
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims 3
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 claims 3
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 3
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 3
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 3
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims 3
- 102100034256 Mucin-1 Human genes 0.000 claims 3
- 108010008707 Mucin-1 Proteins 0.000 claims 3
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 claims 3
- 102000036673 PRAME Human genes 0.000 claims 3
- 108060006580 PRAME Proteins 0.000 claims 3
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 3
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 claims 3
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 3
- 102000000763 Survivin Human genes 0.000 claims 3
- 108010002687 Survivin Proteins 0.000 claims 3
- 108010017842 Telomerase Proteins 0.000 claims 3
- 102000003425 Tyrosinase Human genes 0.000 claims 3
- 108060008724 Tyrosinase Proteins 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 238000012737 microarray-based gene expression Methods 0.000 claims 3
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 3
- 239000007764 o/w emulsion Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 235000002020 sage Nutrition 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 235000010384 tocopherol Nutrition 0.000 claims 2
- 229960001295 tocopherol Drugs 0.000 claims 2
- 229930003799 tocopherol Natural products 0.000 claims 2
- 239000011732 tocopherol Substances 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 241000589968 Borrelia Species 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
- 201000006082 Chickenpox Diseases 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 241001647372 Chlamydia pneumoniae Species 0.000 claims 1
- 241000606153 Chlamydia trachomatis Species 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000588722 Escherichia Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 241000589989 Helicobacter Species 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000724675 Hepatitis E virus Species 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 241000186781 Listeria Species 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000588621 Moraxella Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 241000588653 Neisseria Species 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 241000224016 Plasmodium Species 0.000 claims 1
- 241000223960 Plasmodium falciparum Species 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- 241000223996 Toxoplasma Species 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010046980 Varicella Diseases 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 1
- 239000013043 chemical agent Substances 0.000 claims 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 231100000249 enterotoxic Toxicity 0.000 claims 1
- 230000002242 enterotoxic effect Effects 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0323965.4A GB0323965D0 (en) | 2003-10-13 | 2003-10-13 | Immunogenic compositions |
| GB0323965.4 | 2003-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006111847A true RU2006111847A (ru) | 2007-11-20 |
Family
ID=29559205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006111847/13A RU2006111847A (ru) | 2003-10-13 | 2004-10-11 | Вакцинные композиции, содержащие интерлейкин 18 и сапониновую адъювантную систему |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20070212329A1 (enExample) |
| EP (1) | EP1687025A1 (enExample) |
| JP (1) | JP2007508272A (enExample) |
| KR (1) | KR20070054136A (enExample) |
| CN (1) | CN1889977A (enExample) |
| AU (1) | AU2004283457A1 (enExample) |
| BR (1) | BRPI0415304A (enExample) |
| CA (1) | CA2541695A1 (enExample) |
| CO (1) | CO5700790A2 (enExample) |
| GB (1) | GB0323965D0 (enExample) |
| IL (1) | IL174544A0 (enExample) |
| IS (1) | IS8374A (enExample) |
| MA (1) | MA28149A1 (enExample) |
| NO (1) | NO20061912L (enExample) |
| RU (1) | RU2006111847A (enExample) |
| WO (1) | WO2005039634A1 (enExample) |
| ZA (1) | ZA200602950B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2482866C2 (ru) * | 2010-10-07 | 2013-05-27 | Общество с ограниченной ответственностью "Аллоферон" | Способ лечения папилломавирусных инфекций, реализуемый через индукцию интерлейкина-18 |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2399148A1 (en) * | 2000-02-10 | 2001-08-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| US7727561B2 (en) | 2001-08-31 | 2010-06-01 | Pacific Arrow Limited | Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| US7524824B2 (en) * | 2003-09-04 | 2009-04-28 | Pacific Arrow Limited | Composition comprising Xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| US7884083B2 (en) * | 2002-08-12 | 2011-02-08 | Dynavax Technologies Corporation | Immunomodulatory compositions, methods of making, and methods of use thereof |
| US7488753B2 (en) * | 2003-10-09 | 2009-02-10 | Pacific Arrow Limited | Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof |
| JP4815558B2 (ja) * | 2003-10-09 | 2011-11-16 | パシフィック アロー リミテッド | Ｘａｎｔｈｏｃｅｒａｓｓｏｒｂｉｆｏｌｉａ抽出物を含む組成物、該抽出物から単離された化合物、それらを調製する方法、およびそれらの使用 |
| US7514412B2 (en) * | 2003-10-09 | 2009-04-07 | Pacific Arrow Limited | Anticancer biangeloyl saponins |
| US8614197B2 (en) * | 2003-10-09 | 2013-12-24 | Pacific Arrow Limited | Anti-tumor compounds with angeloyl groups |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| DE102004022200B4 (de) | 2004-05-05 | 2006-07-20 | Actinium Pharmaceuticals, Inc. | Radium-Target sowie Verfahren zu seiner Herstellung |
| US9382285B2 (en) | 2004-09-07 | 2016-07-05 | Pacific Arrow Limited | Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells |
| US8735558B2 (en) * | 2005-02-14 | 2014-05-27 | Pacific Arrow Limited | Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof |
| US8586719B2 (en) * | 2005-04-27 | 2013-11-19 | Pacific Arrow Limited | Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents |
| DE102006008023B4 (de) | 2006-02-21 | 2008-05-29 | Actinium Pharmaceuticals, Inc. | Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets |
| CA2662932C (en) | 2006-09-08 | 2017-06-06 | Actinium Pharmaceuticals, Inc. | Method for the purification of radium from different sources |
| WO2008112125A1 (en) * | 2007-03-09 | 2008-09-18 | Merck & Co., Inc. | Papillomavirus vaccine compositions |
| EP2197497B1 (en) | 2007-09-27 | 2016-06-01 | ImmunoVaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| CN101969976A (zh) | 2008-01-11 | 2011-02-09 | 美国政府健康与人类服务部秘书处 | 针对分枝杆菌的多肽疫苗和接种策略 |
| AU2009253780B2 (en) | 2008-06-05 | 2014-08-14 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| SI3056214T1 (sl) * | 2008-06-27 | 2019-06-28 | Zoetis Services Llc | Nove pomožne sestavine |
| TWI351288B (en) * | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
| AU2009348078B2 (en) * | 2009-06-19 | 2013-03-14 | Eyegene Inc. | Vaccine for cervical cancer |
| US9434677B2 (en) | 2009-07-16 | 2016-09-06 | Pacific Arrow Limited | Natural and synthetic compounds for treating cancer and other diseases |
| US20120277308A1 (en) | 2010-07-16 | 2012-11-01 | Pacific Arrow Limited | compounds for treating cancer and other diseases |
| US9499577B2 (en) | 2009-07-16 | 2016-11-22 | Pacific Arrow Limited | Natural and synthetic compounds for treating cancer and other diseases |
| PL2528621T3 (pl) * | 2010-01-27 | 2017-07-31 | Glaxosmithkline Biologicals S.A. | Zmodyfikowane antygeny gruźlicy |
| JP6034285B2 (ja) * | 2010-05-28 | 2016-11-30 | ゾエティス・ベルジャム・エス・アー | 抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用 |
| GB201016471D0 (en) * | 2010-09-30 | 2010-11-17 | Isis Innovation | Viral vector immunogenic compositions |
| CN113876945A (zh) | 2011-10-06 | 2022-01-04 | 免疫疫苗技术有限公司 | 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用 |
| GB201205361D0 (en) * | 2012-03-27 | 2012-05-09 | Univ Nottingham Trent | Breast cancer assay |
| CA3044471C (en) * | 2013-01-04 | 2021-05-11 | Obi Pharma, Inc. | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant |
| US10166288B2 (en) * | 2014-10-01 | 2019-01-01 | The Trustees Of The University Of Pennsylvania | Vaccines having an antigen and interleukin-21 as an adjuvant |
| US10456459B2 (en) | 2015-07-20 | 2019-10-29 | Zoetis Services Llc | Liposomal adjuvant compositions |
| GB201522329D0 (en) * | 2015-12-17 | 2016-02-03 | Glaxosmithkline Biolog S A And Inst Nat De La Sante Et De La Rech Medicale Inserm And Université Pie | Use of adjuvants for the prevention and/or treatment of autoimmune diseases |
| JP6963019B2 (ja) * | 2016-10-31 | 2021-11-05 | アイジーン インコーポレイテッドEyegene Inc. | 免疫調節剤及び陽イオン性リポソームを含む免疫増強用組成物及びその用途 |
| CU24534B1 (es) * | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
| CN107952069A (zh) * | 2017-11-24 | 2018-04-24 | 长春百克生物科技股份公司 | 重组疫苗及其应用 |
| EP3669890A1 (en) * | 2018-12-18 | 2020-06-24 | Croda International PLC | Filamentous nanoparticles having vaccine adjuvant effect |
| TR201907085A2 (tr) | 2019-05-10 | 2020-11-23 | Univ Yeditepe | Parazi̇tleri̇n ve parazi̇tlerden elde edi̇len ekstraselüler vezi̇külleri̇n kanser tedavi̇si̇nde kullanimi |
| CN114466659A (zh) * | 2019-09-09 | 2022-05-10 | 葛兰素史克生物有限公司 | 免疫治疗组合物 |
| JP7779838B2 (ja) * | 2019-12-13 | 2025-12-03 | 遠大賽威信生命科学（南京）有限公司 | 免疫刺激性組成物及びその用途 |
| WO2022034555A1 (en) * | 2020-08-13 | 2022-02-17 | Janssen Biopharma, Inc. | Polynucleotide constructs and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0761231B1 (en) * | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6355256B1 (en) * | 1994-09-30 | 2002-03-12 | Ludwig Institute For Cancer Research | Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof |
| GB9712347D0 (en) * | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| EP1075275A1 (en) * | 1998-05-07 | 2001-02-14 | Akzo Nobel N.V. | Use of interleukin-18 as vaccine adjuvant |
| US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| TR200103018T2 (tr) * | 1999-04-19 | 2002-02-21 | Beecham Biologicals S.A. Smithkline | İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri. |
| US6843987B2 (en) * | 2000-02-02 | 2005-01-18 | Schering Corporation | Mammalian cytokines; receptors; related reagents and methods |
| CA2399148A1 (en) * | 2000-02-10 | 2001-08-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
-
2003
- 2003-10-13 GB GBGB0323965.4A patent/GB0323965D0/en not_active Ceased
-
2004
- 2004-10-11 US US10/575,838 patent/US20070212329A1/en not_active Abandoned
- 2004-10-11 RU RU2006111847/13A patent/RU2006111847A/ru not_active Application Discontinuation
- 2004-10-11 CN CNA2004800363071A patent/CN1889977A/zh active Pending
- 2004-10-11 AU AU2004283457A patent/AU2004283457A1/en not_active Abandoned
- 2004-10-11 JP JP2006530155A patent/JP2007508272A/ja active Pending
- 2004-10-11 BR BRPI0415304-9A patent/BRPI0415304A/pt not_active Application Discontinuation
- 2004-10-11 WO PCT/EP2004/011620 patent/WO2005039634A1/en not_active Ceased
- 2004-10-11 KR KR1020067009283A patent/KR20070054136A/ko not_active Withdrawn
- 2004-10-11 CA CA002541695A patent/CA2541695A1/en not_active Abandoned
- 2004-10-11 EP EP04790465A patent/EP1687025A1/en not_active Withdrawn
-
2006
- 2006-03-23 IL IL174544A patent/IL174544A0/en unknown
- 2006-03-27 IS IS8374A patent/IS8374A/is unknown
- 2006-04-07 CO CO06034535A patent/CO5700790A2/es not_active Application Discontinuation
- 2006-04-11 ZA ZA200602950A patent/ZA200602950B/xx unknown
- 2006-04-28 NO NO20061912A patent/NO20061912L/no not_active Application Discontinuation
- 2006-05-04 MA MA29002A patent/MA28149A1/fr unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2482866C2 (ru) * | 2010-10-07 | 2013-05-27 | Общество с ограниченной ответственностью "Аллоферон" | Способ лечения папилломавирусных инфекций, реализуемый через индукцию интерлейкина-18 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2541695A1 (en) | 2005-05-06 |
| WO2005039634A1 (en) | 2005-05-06 |
| IL174544A0 (en) | 2006-08-01 |
| AU2004283457A1 (en) | 2005-05-06 |
| US20070212329A1 (en) | 2007-09-13 |
| EP1687025A1 (en) | 2006-08-09 |
| KR20070054136A (ko) | 2007-05-28 |
| MA28149A1 (fr) | 2006-09-01 |
| CO5700790A2 (es) | 2006-11-30 |
| ZA200602950B (en) | 2007-09-26 |
| CN1889977A (zh) | 2007-01-03 |
| GB0323965D0 (en) | 2003-11-19 |
| NO20061912L (no) | 2006-06-02 |
| IS8374A (is) | 2006-03-27 |
| JP2007508272A (ja) | 2007-04-05 |
| BRPI0415304A (pt) | 2006-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006111847A (ru) | Вакцинные композиции, содержащие интерлейкин 18 и сапониновую адъювантную систему | |
| JP2007508272A5 (enExample) | ||
| RU2006111849A (ru) | Иммуногенные композиции | |
| Lacaille-Dubois | Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review | |
| ES2331952T3 (es) | Fraccion de quil a con baja toxicidad y su uso. | |
| JP2007508273A5 (enExample) | ||
| Lee et al. | Recent advances of vaccine adjuvants for infectious diseases | |
| O'Hagan et al. | Recent developments in adjuvants for vaccines against infectious diseases | |
| Ioannou et al. | CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein | |
| RU2118164C1 (ru) | Вакцинная композиция, обладающая свойством вызывать цитолитический т-клеточный ответ у млекопитающих, способ получения цитолитического т-клеточного ответа in vivo, способ получения вакцины | |
| Weinberger et al. | Vaccines for the elderly | |
| JP4805242B2 (ja) | ワクチン | |
| ES2285036T3 (es) | Coadyuvantes basados en una emulsion y mpl para vacunas. | |
| RU2004135541A (ru) | Иммуногенные композиции | |
| JP2004511529A (ja) | 免疫刺激性オリゴヌクレオチドおよびトコールを含むアジュバント組成物 | |
| US20120288515A1 (en) | Synthetic long peptide (slp)-based vaccines | |
| AU2002310802B2 (en) | Multivalent vaccine comprising an HIV antigen and an HSV antigen and/or an HPV antigen | |
| KR101361769B1 (ko) | Ｈｐｖ-16 ｌ1 ｖｌｐ 및 ｈｐｖ-18 ｌ1 ｖｌｐ 백신 | |
| JP5307859B2 (ja) | ワクチン | |
| CN1980691A (zh) | 用于癌症免疫疗法的基于mage－3和ny－eso－1的多价疫苗 | |
| Barraclough et al. | Hepatitis B virus infection in hemodialysis populations: progress toward prevention | |
| Gupta et al. | Adjuvants for Antigens in Vaccines | |
| Garçon | Chance and necessity | |
| Katayama et al. | Influence of antigenic forms and adjuvants on protection against a lethal infection of Aujeszky’s disease virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20080226 |